- Securing a new treatment option for multiple myeloma patients and advancing domestic approval and commercialization
- Expected to enhance price competitiveness and improve patient access to treatment
[by Jin, Yu Jeong] GC Cell announced on October 29 that it has entered into a domestic licensing agreement with China’s Nanjing IASO Biotechnology (hereinafter referred to as IASO Bio) for the distribution of Fucaso, the company's chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of multiple myeloma, in the Korean market.
The agreement is intended to introduce a new therapeutic option for multiple myeloma patients in Korea, with plans to gradually pursue regulatory approval and commercialization of 바카라사이트 승리바카라 소울카지노.
Multiple myeloma is a difficult-to-treat hematologic malignancy characterized by high relapse rates and resistance, predominantly affecting older adults. In Korea, the incidence of this disease continues to rise each year, driven by the aging population. Despite recent improvements in first-line treatment accessibility through insurance coverage of certain combination regimens, therapeutic options remain limited for patients exhibiting resistance or refractory to existing treatments. Furthermore, the high cost of CAR-T 바카라사이트 승리바카라 소울카지노 therapies and the insufficient clinical infrastructure to support patients in the fourth or later lines of treatment pose significant challenges to ensuring equitable and practical access to care.
Fucaso, a B-바카라사이트 승리바카라 소울카지노 maturation antigen (BCMA)-targeting CAR-T 바카라사이트 승리바카라 소울카지노 therapy developed by IASO Bio, received regulatory approval in China in June 2023 and is currently being prescribed to Chinese patients. With its competitive pricing, Fucaso is expected to significantly improve treatment access for patients in need.
GC Cell has been preparing for the introduction of Fucaso since H1 2025 in Korea. The company obtained approval from the Ministry of Food and Drug Safety (MFDS) for its designation as an ‘orphan drug’ in July, followed by recognition as an ‘advanced biopharmaceutical eligible for fast-track processing’ in August. Moving forward, GC Cell aims to establish a stable and efficient supply chain to ensure that patients can receive cost-effective treatment in a timely manner.
"This agreement marks a significant milestone for us as a Korean cell therapy company, laying the foundation for CAR-T commercialization. We are committed to stabilizing the supply chain to ensure that patients can access treatment at a more reasonable cost," said Won Sung-yong, CEO of GC Cell.
“This partnership represents a major milestone in our company’s global expansion strategy,” stated Zhang Jin-hua, CEO of IASO Bio. “By demonstrating Fucaso’s international potential, we anticipate that GC Cell’s strong commercialization capabilities will enable us to deliver innovative therapies to a broader group of patients in the Korean market,” she added.